Cite
HARVARD Citation
Coens, C. et al. (n.d.). 1278PHealth-related quality-of-life results for pembrolizumab versus placebo after complete resection of high-risk stage III melanoma from the EORTC 1325-MG/Keynote 054 trial: An international randomized double-blind phase III trial. Annals of oncology. p. . [Online].